U.S., Aug. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07784725) titled 'A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus' on Aug. 05.
Brief Summary: The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment
Study Start Date: Aug. 19
Study Type: INTERVENTIONAL
Condition:
Obesity or Overweight
Intervention:
DRUG: AZD6234
IMP injected subcutaneously, once a week. Unit dose strength as per CSP.
DRUG: Placebo
Placebo matching IMP dose ...